News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Revenue from operations up 26% to Rs. 768 crores
Extended Phenytoin Sodium Capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
The company increases its efficiency and is able to face the growing demand for its services.
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Transformation to pure-play Innovative Medicines company nears completion
SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.
Subscribe To Our Newsletter & Stay Updated
